Novo Nordisk has announced a multi-billion dollar expansion of its manufacturing capacity to accommodate new therapies and increase the production of already approved products, including the GLP-1 therapies for diabetes and weight loss.
Novo Nordisk has announced a significant expansion in manufacturing capacity
November 13, 2023 Latest NewsBioPharma
Latest Video
New Stories
-
The need to break this paradigm if we are serious about meaningful reform
June 22, 2026 - - Latest News -
It seems that one critical stakeholder group is missing in this website design
June 22, 2026 - - Latest News -
May 2026 delivers paediatric dosing flexibility, vaccine decisions, and policy updates
June 22, 2026 - - Latest News -
CSL executive Elizabeth Rex joins AusBiotech board as observer
June 22, 2026 - - Latest News -
The 'Dispatched' Week in Review Podcast - 19 June
June 19, 2026 - - Podcast -
Gilead rushes remdesivir to Uganda to support Ebola response
June 19, 2026 - - Latest News -
Infectious diseases across the lifespan are a hidden burden beyond the acute episode
June 19, 2026 - - Latest News

